What's Happening?
Avo, a clinical AI platform, has secured $10 million in Series A funding led by Noro-Moseley Partners, with participation from AlleyCorp and other investors. The platform integrates with major EHR systems like Epic and MEDITECH, using AI copilots to streamline
documentation and clinical decision-making. Avo has partnered with EBSCO Clinical Decisions to incorporate DynaMed, an evidence-based clinical decision support tool, into its platform. This integration aims to provide clinicians with reliable, real-time information, reducing the risk of AI-generated errors in medical advice.
Why It's Important?
The funding and partnership with DynaMed position Avo to significantly impact the clinical decision support market by offering a platform that combines AI with evidence-based guidelines. This approach addresses the challenge of AI 'hallucinations' in healthcare, where AI might generate inaccurate medical advice. By grounding AI in reliable data, Avo enhances the accuracy of clinical decisions, potentially improving patient outcomes and operational efficiency in hospitals. The platform's ability to demonstrate a return on investment is crucial in a market where healthcare providers are under financial pressure.
